復星醫藥(02196.HK)擬出售上海克隆100%股權及債權 交易對價不超過12.56億元
格隆匯9月26日丨復星醫藥(02196.HK)公告,爲進一步聚焦核心業務並提升資產運營效率,控股子公司復星醫藥產業擬籌劃轉讓上海克隆100%股權(其主要資產爲位於上海市徐彙區宜山路1289號的標的物業),本次交易步驟及結構如下:
1、控股子公司復星醫藥產業擬作爲LP現金出資人民幣5,460萬元與弘毅天津、中匯人壽共同出資設立專項基金(即本次投資),預計持有該基金足額募集後9.98%的財產份額;
2、於專項基金設立並滿足約定條件後,控股子公司復星醫藥產業擬以不超過人民幣125,600萬元向專項基金或其控制的實體轉讓所持有的上海克隆100%的股權和對上海克隆享有的債權(即本次轉讓)。
本次轉讓完成後,集團將不再直接持有上海克隆的股權,但仍將繼續租賃部分標的物業作爲經營場所,預計本次轉讓不會對集團之日常運營造成重大影響。本次轉讓所得款項將用於集團創新藥業務的持續投入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.